ITVA20060041A1 - USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE - Google Patents

USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE

Info

Publication number
ITVA20060041A1
ITVA20060041A1 IT000041A ITVA20060041A ITVA20060041A1 IT VA20060041 A1 ITVA20060041 A1 IT VA20060041A1 IT 000041 A IT000041 A IT 000041A IT VA20060041 A ITVA20060041 A IT VA20060041A IT VA20060041 A1 ITVA20060041 A1 IT VA20060041A1
Authority
IT
Italy
Prior art keywords
adminotiazolic
huntington
disease
derivatives
compounds
Prior art date
Application number
IT000041A
Other languages
Italian (it)
Inventor
Elena Cattaneo
Aleksey Kazantsev
Dorotea Rigamonti
Original Assignee
Dialectica Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dialectica Srl filed Critical Dialectica Srl
Priority to IT000041A priority Critical patent/ITVA20060041A1/en
Priority to PCT/EP2007/006007 priority patent/WO2008003511A1/en
Publication of ITVA20060041A1 publication Critical patent/ITVA20060041A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000041A 2006-07-05 2006-07-05 USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE ITVA20060041A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT000041A ITVA20060041A1 (en) 2006-07-05 2006-07-05 USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE
PCT/EP2007/006007 WO2008003511A1 (en) 2006-07-05 2007-07-03 Use of aminothiazole derivative compounds, pharmaceutical compositions thereof, in the treatment of diseases characterized by abnormal repression of gene transcription, particularly huntington's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000041A ITVA20060041A1 (en) 2006-07-05 2006-07-05 USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE

Publications (1)

Publication Number Publication Date
ITVA20060041A1 true ITVA20060041A1 (en) 2008-01-06

Family

ID=38514960

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000041A ITVA20060041A1 (en) 2006-07-05 2006-07-05 USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE

Country Status (2)

Country Link
IT (1) ITVA20060041A1 (en)
WO (1) WO2008003511A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101679409B (en) 2006-12-22 2014-11-26 Astex治疗学有限公司 Bicyclic heterocyclic derivative compound, pharmaceutical compositions and uses thereof
US7892830B2 (en) 2007-01-17 2011-02-22 Wisconsin Alumni Research Foundation Clonal culture of human pluripotent stem cells
CN101730699A (en) 2007-03-21 2010-06-09 百时美施贵宝公司 Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
EA027418B1 (en) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES, PHARMACEUTICAL COMPOSITION BASED THEREON, PROCESSES FOR PREPARING AND USING THE SAME, INTERMEDIATES
RU2657540C2 (en) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4]triazolo[4,3-a]quinoxaline compounds and pde 10 inhibitors for use in treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US20220002296A1 (en) * 2018-11-27 2022-01-06 Rutgers, The State University Of New Jersey Pharmaceutical compounds and therapeutic methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201194D0 (en) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
BRPI0517253A (en) * 2004-10-28 2008-10-07 Irm Llc compounds and compositions as hedgehog trajectory modulators

Also Published As

Publication number Publication date
WO2008003511A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ITVA20060041A1 (en) USE OF COMPOUNDS ADMINOTIAZOLIC DERIVATIVES, OF THEIR PHARMACEUTICAL COMPOSITIONS, IN THE TREATMENT OF DISEASES CHARACTERIZED BY THE ABNORMAL REPRESSION OF GENE TRANSCRIPTION, PARTICULARLY THE HUNTINGTON'S DISEASE
UY30711A1 (en) NEW DERIVATIVES OF 1,4-BENZOTIEPINA-1, 1-CIOXIDE, METHOD FOR PREPARATION, PHARMACEUTICAL PRODUCTS THAT INCLUDE THESE COMPOUNDS AND THEIR USE.-
UY31314A1 (en) HETEROCICLIC AMIDAS AND ITS METHODS OF USE-976
GT200900095A (en) REPLACED DIHYDROPIRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HERMATOLOGICAL DISEASES.
CL2007001131A1 (en) COMPOUNDS DERIVED FROM REPLACED PURINA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE RESPIRATORY ROADS.
UY30712A1 (en) NEW DERIVATIVES OF 1, 4-BENZOTIEPINA-1, 1-DIOXIDE REPLACED WITH FLUOR, METHOD FOR PREPARATION, PHARMACEUTICAL PRODUCTS THAT UNDERSTAND THESE COMPOUNDS AND THEIR USE.
MX2009006704A (en) New compounds.
CL2009002206A1 (en) Compounds derived from pyrrolo - (2-3-d] -pyrimidin-7 (6h) -tetrahydrofuran-2-yl phosphonamidate, pharmaceutical composition; and its use in the treatment of viral diseases.
UY30444A1 (en) PIRIMIDINE DERIVATIVES, PROCESSES FOR PREPARATION, PHARMACCUTIC COMPOSITIONS AND USES OF THE SAME.
DK2024352T3 (en) Glucopyranosyl substituted benzo nitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their preparation
CL2008003940A1 (en) Compounds derived from substituted morpholino pyrimidine; pharmaceutical composition comprising said compounds; and its use for the treatment of cancer, inflammatory diseases, obstructive diseases of the airways, immune diseases or cardiovascular diseases.
BRPI0915084B8 (en) compound, and, pharmaceutical composition
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
BRPI0518993A2 (en) compound or a pharmaceutically acceptable salt, solvate or ester thereof, pharmaceutical composition, and use of a compound
DOP2009000165A (en) DERIVATIVES OF REPLACED OXINDOL, MEDICATIONS THAT UNDERSTAND AND USE THEMSELVES
MX2010004965A (en) Amide derivatives as sirtuin modulators.
EA201290267A1 (en) DERIVATIVES OF DIOXABICICLO [3.2.1] OKTAN-2,3,4-TRIOL
GT200600081A (en) ACETYLENE DERIVATIVES
BRPI0607413A2 (en) pharmaceutical composition comprising indolylmaleimide derivatives
HN2008001393A (en) DERIVATIVES OF 1,2,4,5- TETRAHIDRO -3H- BENZAZEPINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE412636T1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AN AGAINST OBESITY
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
CR10497A (en) USEFUL PIPERAZINYL DERIVATIVES IN THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEIVER
PT2056804E (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
IL204126A (en) 1,3-dihydroisoindole derivatives, process for their preparation, use thereof, medicaments comprising them, kit and intermediates thereof